Clinical trial
A Single-arm, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of Toripalimab Injection (JS001) in the Treatment of Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy and Are Positive Specific Markers
NCT04603040 is registered in ClinicalTrials.gov with Shanghai Junshi Bioscience Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-arm, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of Toripalimab Injection (JS001) in the Treatment of Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy and Are Positive Specific Markers
- Lead sponsor
- Shanghai Junshi Bioscience Co., Ltd.
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- September 28, 2020
- Completion date
- March 27, 2023
- Enrollment
- 17 (actual)
- Sites
- 39
Conditions
As the registry lists them; a condition with its own page is linked.
recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma who have failed at least two prior lines of therapy